Company attributes
Other attributes
Synapse Biomedical Inc (SBI) is a company founded in September 2002 by Anthony Ignagni to commercialize the NeuRx Diaphragm Pacing System (DPS). The electrical stimulation system was developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland for the treatment of chronic respiratory insufficiency. The innovative system allows technology to meet clinical needs in spinal cord injuries, diaphragm conditioning in muscular dystrophies (such as ALS) and respiratory short-term intensive care settings.
In September 2011 Synapse Biomedical announced that the U.S. Food and Drug Administration (FDA) approved its NeuRx DPS for treating amyotrophic lateral sclerosis (ALS) patients who have stimulatable diaphragms and are experiencing chronic hypoventilation.
Synapse Biomedical's headquarters are located in Oberlin, Ohio. The company has a European office located in the Enghien-Les-Bains suburb of Paris, France.
The company has partnered with treatment centers in 24 countries that have skilled Board Certified Laparoscopic Surgeons qualified to perform the NeuRx DPS® implantation procedure.
